PMID: 8599997Jan 1, 1996Paper

A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study

European Journal of Haematology
F Di RaimondoR Giustolisi

Abstract

The use of recombinant erythropoietin for treatment of anemia in myelodysplastic patients has so far produced poorer results than expected. Most clinical studies have been conducted without any selection of patients. In the present study we report our experience with the use of rhEPO in a population of selected MDS subjects. Only patients affected by refractory anemia according to FAB criteria, without significant WBC and platelets reduction, with normal LDH and short history of disease were eligible for the study and were treated with rhEPO at a dosage of 150 mg/kg three times a week for 2 months. Among the 12 so treated patients, 7 (58.3%) achieved complete remission, 2 partial remission and 3 failed to respond. This high response rate makes more than acceptable the cost/benefit ratio for rhEPO in RA patients and may identify a subgroup of patients that can be treated successfully with rhEPO alone.

Citations

Dec 4, 2010·Experimental Biology and Medicine·James W Fisher
Jan 25, 2003·British Journal of Haematology·David BowenUNKNOWN UK MDS Guidelines Group
Jan 14, 2003·Experimental Biology and Medicine·James W Fisher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.